Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 62% of modeled bridge. Risks: Occupancy Rate, Revenue per Bed. Risk-adjusted uplift: $1.8M (vs $2.9M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $1.1M | $1.1M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $1.1M | $30K | $1.1M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $168K | $499K | $668K | $2.1M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $35K | $35K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 30.6% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $274K | $549K | $823K | $1.1M | $1.1M | $1.1M | $1.1M |
| Denial Rate Reduction | $0 | $272K | $543K | $815K | $1.1M | $1.1M | $1.1M | $1.1M |
| A/R Days Reduction | $0 | $223K | $445K | $668K | $668K | $668K | $668K | $668K |
| Clean Claim Rate | $0 | $18K | $35K | $35K | $35K | $35K | $35K | $35K |
| Cumulative | $0 | $786K | $1.6M | $2.3M | $2.9M | $2.9M | $2.9M | $2.9M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $2.9M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 67% / 12.9x | 71% / 14.7x | 75% / 16.5x | 77% / 17.4x | 79% / 18.2x |
| 9.0x | 62% / 11.1x | 66% / 12.7x | 70% / 14.3x | 72% / 15.1x | 74% / 15.9x |
| 10.0x | 57% / 9.7x | 62% / 11.1x | 66% / 12.5x | 68% / 13.2x | 69% / 13.9x |
| 11.0x | 53% / 8.5x | 58% / 9.8x | 62% / 11.1x | 64% / 11.7x | 65% / 12.4x |
| 12.0x | 50% / 7.5x | 54% / 8.7x | 58% / 9.9x | 60% / 10.5x | 62% / 11.1x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 36% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 4.1x, adding 4.3 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $2.8M | — | $2.8M | 5.0% |
| Year 1 | $2.8M | +$1.9M | $4.8M | 8.7% |
| Year 2 | $2.9M | +$2.9M | $5.8M | 10.6% |
| Year 3 | $3.0M | +$2.9M | $5.9M | 10.8% |
| Year 4 | $3.1M | +$2.9M | $6.0M | 10.9% |
| Year 5 | $3.2M | +$2.9M | $6.1M | 11.1% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $549K | $823K | $1.1M | $1.3M |
| Denial Rate Reductio | $543K | $815K | $1.1M | $1.3M |
| A/R Days Reduction | $334K | $501K | $668K | $801K |
| Clean Claim Rate | $18K | $26K | $35K | $42K |
| Total | $1.4M | $2.2M | $2.9M | $3.5M |
Peer Context — Where This Hospital Sits
Key metrics vs 172 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 5.0% | -20.8% | -4.7% | 4.2% | P78 |
| Net-to-Gross | 21.4% | 17.6% | 22.3% | 30.6% | P42 |
| Occupancy | 27.7% | 43.7% | 57.5% | 72.5% | P9 |
| Rev/Bed | $518K | $550K | $984K | $2.1M | P23 |
| Exp/Bed | $492K | $624K | $1.1M | $2.3M | P18 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.